Your browser doesn't support javascript.
loading
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai, Renáta; Zimmer, Lisa; Al-Matary, Yahya; Kaptein, Paulien; Albrecht, Lea J; Shannan, Batool; Brase, Jan C; Gusenleitner, Daniel; Amaral, Teresa; Wyss, Nina; Utikal, Jochen; Flatz, Lukas; Rambow, Florian; Reinhardt, Hans Christian; Dick, Jenny; Engel, Daniel R; Horn, Susanne; Ugurel, Selma; Sondermann, Wiebke; Livingstone, Elisabeth; Sucker, Antje; Paschen, Annette; Zhao, Fang; Placke, Jan M; Klose, Jasmin M; Fendler, Wolfgang P; Thommen, Daniela S; Helfrich, Iris; Schadendorf, Dirk; Roesch, Alexander.
Afiliación
  • Váraljai R; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Al-Matary Y; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Kaptein P; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Albrecht LJ; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Shannan B; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Brase JC; Novartis Pharma AG, Basel, Switzerland.
  • Gusenleitner D; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
  • Amaral T; Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
  • Wyss N; Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland.
  • Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Flatz L; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany.
  • Rambow F; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
  • Reinhardt HC; Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
  • Dick J; Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland.
  • Engel DR; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Horn S; Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, Essen, Germany.
  • Ugurel S; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
  • Sondermann W; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.
  • Livingstone E; Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
  • Sucker A; Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
  • Paschen A; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Zhao F; Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.
  • Placke JM; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Klose JM; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Fendler WP; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Thommen DS; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Helfrich I; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Schadendorf D; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.
  • Roesch A; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Nat Cancer ; 4(9): 1395, 2023 Sep.
Article en En | MEDLINE | ID: mdl-37580519
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Cancer Año: 2023 Tipo del documento: Article País de afiliación: Alemania